Skip to Content

Polydex Pharmaceuticals Ltd POLXF

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Polydex Pharmaceuticals Ltd is engaged in the development, manufacturing, and marketing of biotechnology-based products for the human pharmaceutical market. In addition, it also engaged in the manufacture and sale of veterinary pharmaceutical products and specialty chemicals. It focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. Geographically sale of the products can be seen amplifying in the region of Europe, United States, Canada, and other countries of which the United States region accounts for the larger share of revenue.

421 Comstock Road
Toronto, ON, M1L 2H5, Canada
T +1 416 755-2231
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jan 31, 2010
Fiscal Year End Jan 31, 2022
Stock Type
Employees 21